Acute profound thrombocytopenia without bleeding complications after abciximab administration

Area of Science:

• Cardiology
• Hematology
• Immunology

Background:

• Abciximab (c7E3) is a monoclonal antibody fragment targeting platelet glycoprotein IIb/IIIa.
• It is the first FDA-approved inhibitor of platelet receptor glycoproteins.
• Severe thrombocytopenia (< 50 x 10^9/L) is a rare complication of abciximab therapy.

Observation:

• The EPIC study reported severe thrombocytopenia in 1.6% of patients receiving abciximab.
• Bleeding complications were common in patients with abciximab-induced thrombocytopenia.
• Intravenous IgG was not effective, and corticosteroid use was not previously reported.

Findings:

• A case of acute profound thrombocytopenia after abciximab administration is presented.
• Treatment involved platelet transfusion combined with intravenous corticosteroids.
• This approach successfully reversed thrombocytopenia without causing bleeding complications.

Implications:

• This case suggests a potential effective treatment strategy for abciximab-induced thrombocytopenia.
• Combined therapy may prevent bleeding in patients experiencing this rare adverse event.
• Further research into corticosteroid efficacy for abciximab-related thrombocytopenia is warranted.